Advances in Cancer Research最新文献_第8页

Strategies to mitigate the toxicity of cancer therapeutics. 减轻癌症治疗药物毒性的策略。

2区医学

Advances in Cancer Research Pub Date : 2022-01-01 Epub Date: 2022-03-21 DOI: 10.1016/bs.acr.2022.02.006

Adriana M Kahn, Kim R M Blenman, Steve T Sonis, Maryam B Lustberg

{"title":"Strategies to mitigate the toxicity of cancer therapeutics.","authors":"Adriana M Kahn, Kim R M Blenman, Steve T Sonis, Maryam B Lustberg","doi":"10.1016/bs.acr.2022.02.006","DOIUrl":"https://doi.org/10.1016/bs.acr.2022.02.006","url":null,"abstract":"Cancer therapeutics are dynamically evolving, and include traditional chemotherapy and hormone therapy, as well as more recently developed treatment modalities, such as tyrosine kinase inhibitors, monoclonal antibodies and the revolutionary approach based on immune checkpoint inhibition. These regimens are unfortunately not free of adverse events, and patients with cancer are a susceptible population experiencing a myriad of disease and treatment toxicities combined. In this review, we present the latest overview of the management of the most common systemic cancer treatment symptoms and the science of symptom management supporting these strategies. We discuss cancer-related cognitive impairment, ocular toxicity, ototoxicity, oral mucosal toxicities, gastrointestinal toxicities, renal toxicity, aromatase inhibitor-induced musculoskeletal symptoms, chemotherapy-induced peripheral neuropathy, and immunotherapy-induced autoimmunity derived from systemic therapies for cancer. In summary, we review the future directions and ideal goals of symptom science research in order to benefit patients utilizing a comprehensive individualized approach.","PeriodicalId":50875,"journal":{"name":"Advances in Cancer Research","volume":" ","pages":"215-244"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40577648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Preface. 前言。

2区医学

Advances in Cancer Research Pub Date : 2022-01-01 DOI: 10.1016/S0065-230X(22)00067-7

David A Gewirtz, Paul B Fisher

引用次数: 0

Preface. 前言。

2区医学

Advances in Cancer Research Pub Date : 2022-01-01 DOI: 10.1016/S0065-230X(22)00012-4

John P O'Bryan, Gary A Piazza

引用次数: 0

Effect of Chinese herbal medicine on lung disease: an updated review 中药对肺部疾病的作用:最新综述

2区医学

Advances in Cancer Research Pub Date : 2022-01-01 DOI: 10.53388/2022522027

Virender Kumar, Davinder Kumar, N. Khatri, Ashwani Kumar, Joginder Khurana

引用次数: 1

Autophagy-associated long non-coding RNA signature for lung adenocarcinoma 肺腺癌自噬相关的长链非编码RNA特征

2区医学

Advances in Cancer Research Pub Date : 2022-01-01 DOI: 10.53388/2022522003

Yufeng Huang, Jing Xiang, Chun Yuan, B. Deng, Xia Yang, Lianxiang Luo, Zhuoyuan Liang

引用次数: 0

Pandemic adaptation in oncological management-a tertiary care radiation oncology center experience 肿瘤管理中的大流行适应——三级护理放射肿瘤中心经验

2区医学

Advances in Cancer Research Pub Date : 2022-01-01 DOI: 10.53388/2022522004

Dillip Kumar, Sanjeev Kumar, A. Amritt, M. Mishra, Poornima Devi, S. Kumar

引用次数: 0

1,3,4-Oxadiazole as an emerging telomerase inhibitor - a promising anticancer motif 1,3,4-恶二唑作为一种新兴的端粒酶抑制剂-一种有前景的抗癌基序

2区医学

Advances in Cancer Research Pub Date : 2022-01-01 DOI: 10.53388/2022522018

Davinder Kumar, Virender Kumar, H. Kumar, A. Deep, Rakesh Kumar

引用次数: 2

Chemotherapy induced gastrointestinal toxicities. 化疗引起胃肠道毒性。

2区医学

Advances in Cancer Research Pub Date : 2022-01-01 DOI: 10.1016/bs.acr.2022.02.007

Hamid I Akbarali, Karan H Muchhala, Donald K Jessup, Stanley Cheatham

{"title":"Chemotherapy induced gastrointestinal toxicities.","authors":"Hamid I Akbarali, Karan H Muchhala, Donald K Jessup, Stanley Cheatham","doi":"10.1016/bs.acr.2022.02.007","DOIUrl":"https://doi.org/10.1016/bs.acr.2022.02.007","url":null,"abstract":"Chemotherapy-induced gastrointestinal dysfunction is a common occurrence associated with many different classes of chemotherapeutic agents. Gastrointestinal toxicity includes mucositis, diarrhea, and constipation, and can often be a dose-limiting complication, induce cessation of treatment and could be life threatening. The gastrointestinal epithelium is rich in rapidly dividing cells and hence is a prime target for chemotherapeutic drugs. The incidence of gastrointestinal toxicity, including diarrhea and mucositis, is extremely high for a wide array of chemotherapeutic and radiation regimens. In fact, 60%-100% of patients on high-dose chemotherapy suffer from gastrointestinal side effects. Unfortunately, treatment options are limited, and therapy is often restricted to palliative care. Therefore, there is a great unmet therapeutic need for preventing and treating chemotherapy-induced gastrointestinal toxicities in the clinic. In this review, we discuss our current understanding of the mechanisms underlying chemotherapy-induced diarrhea and mucositis, and emerging mechanisms involving the enteric nervous system, smooth muscle cells and enteric immune cells. Recent evidence has also implicated gut dysbiosis in the pathogenesis of not only chemotherapy-induced mucositis and diarrhea, but also chemotherapy-induced peripheral neuropathy. Oxidative stress induced by chemotherapeutic agents results in post-translational modification of ion channels altering neuronal excitability. Thus, investigating how chemotherapy-induced changes in the gut- microbiome axis may lead to gut-related toxicities will be critical in the discovery of new drug targets for mitigating adverse gastrointestinal effects associated with chemotherapy treatment.","PeriodicalId":50875,"journal":{"name":"Advances in Cancer Research","volume":"155 ","pages":"131-166"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10033220/pdf/nihms-1881062.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9151367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 16

Matricellular proteins in intrahepatic cholangiocarcinoma. 肝内胆管癌的基质细胞蛋白。

2区医学

Advances in Cancer Research Pub Date : 2022-01-01 DOI: 10.1016/bs.acr.2022.01.010

Alphonse E Sirica

{"title":"Matricellular proteins in intrahepatic cholangiocarcinoma.","authors":"Alphonse E Sirica","doi":"10.1016/bs.acr.2022.01.010","DOIUrl":"https://doi.org/10.1016/bs.acr.2022.01.010","url":null,"abstract":"Intrahepatic cholangiocarcinoma (iCCA) is typically characterized by a prominent desmoplastic stroma that is often the most dominant feature of the tumor. This tumor reactive stroma is comprised of a dense fibro-collagenous-enriched extracellular matrix (ECM) surrounding the cancer cells, together with other ECM proteins/peptides, specifically secreted matricellular glycoproteins and proteolytic enzymes, growth factors, and cytokines. Moreover, as enjoined by cholangiocarcinoma cells, this enriched tumor microenvironment is populated by various stromal cell types, most prominently, cancer-associated myofibroblasts (CAFs), along with variable numbers of tumor-associated macrophages (TAMs), inflammatory and vascular cell types. While it is now well appreciated that the interplay between cholangiocarcinoma cells, CAFs, and TAMs in particular play a critical role in promoting cholangiocarcinoma progression, therapeutic resistance, and immune evasion, it is also becoming increasingly evident that over-expression and secretion into the tumor microenvironment of functionally overlapping matricellular glycoproteins, including periostin, osteopontin, tenascin-C, thrombospondin-1, mesothelin and others have an important role to play in regulating or modulating a variety of pro-oncogenic cellular functions, including cholangiocarcinoma cell proliferation, invasion, and metastasis, epithelial-mesenchymal transition, ECM remodeling, and immune evasion. Matricellular proteins have also shown promise as potential prognostic factors for iCCA and may provide unique therapeutic opportunities particularly in relation to targeting iCCA pre-metastatic and metastatic niches, tumor cell dormancy, and immune evasion. This review will highlight timely research and its translational implications for salient matricellular proteins in terms of their structure-function relationships, as modulators of intrahepatic cholangiocarcinoma microenvironment and progression, and potential clinical value for iCCA prognosis and therapy.","PeriodicalId":50875,"journal":{"name":"Advances in Cancer Research","volume":"156 ","pages":"249-281"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10371492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

Inhibition of SHP2 as an approach to block RAS-driven cancers. 抑制SHP2作为阻断ras驱动癌症的途径。

2区医学

Advances in Cancer Research Pub Date : 2022-01-01 Epub Date: 2021-08-03 DOI: 10.1016/bs.acr.2021.07.002

Yu-Ting Chou, Trever G Bivona

引用次数: 4